Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: pro...
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Frontiers Media S.A.
2021-02-01
|
| Reeks: | Frontiers in Public Health |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full |